← Back to Search

Air Filtration

Air Filtration for Heart Disease (SAPIA Trial)

N/A
Recruiting
Led By Zhanghua Chen, PhD
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age between 65 and 84 years old
Weight ≥ 110 pounds
Must not have
Have history of degenerative disease of the nervous system such as dementia and Alzheimer's
Currently have active cancer treatments
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions
Awards & highlights

Summary

This trial tests if using special air filters in homes can help people with heart disease by cleaning the air they breathe. The goal is to see if reducing indoor air pollution can slow down the worsening of their heart condition.

Who is the study for?
Adults aged 65-84 living in Los Angeles County with a history of ischemic heart disease, clinically stable for the past 6 months, and weighing at least 110 pounds can join. Smokers or those with certain health conditions like active cancer treatments or degenerative diseases are excluded.
What is being tested?
The trial is testing if using HEPA air filters in homes can slow down the worsening of atherothrombosis (blood clotting in hardened arteries) compared to sham (fake) filters by reducing fine particle pollution indoors.
What are the potential side effects?
Since this trial involves indoor air filtration systems, there are no direct medical side effects expected from participating. However, any unexpected reactions to the equipment will be monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 65 and 84 years old.
Select...
I weigh at least 110 pounds.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a degenerative nervous system condition like dementia or Alzheimer's.
Select...
I am currently undergoing treatment for cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in P-selectin
Change in augmentation index
Change in blood pressure
+2 more
Secondary study objectives
Change in C-reactive protein
Change in fasting glucose
Change in fasting insulin
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Sham first and HEPAExperimental Treatment2 Interventions
This group of participants will be assigned to the intervention of sham filtration with HEPA filter removed at their residence for 9 months first. After 3-month wash-out period, participants will be assigned to the HEPA filtration for 9 months.
Group II: HEPA first and shamExperimental Treatment2 Interventions
This group of participants will be assigned to the intervention of HEPA filtration with the capacity to reduce indoor PM2.5 levels at their residence for 9 months first. After 3-month wash-out period, participants will be assigned to sham filters (air purifier has the same appearance but HEPA filter is removed) for 9 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HEPA filtration
2009
N/A
~50

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Indoor air filtration systems work by removing fine particulate matter (PM2.5) from the air, which can penetrate deep into the lungs and enter the bloodstream. These systems typically use high-efficiency particulate air (HEPA) filters to trap particles as small as 0.3 microns. Reducing PM2.5 exposure is crucial for patients with ischemic heart disease because these particles can exacerbate cardiovascular conditions by promoting inflammation and atherothrombosis. By lowering indoor PM2.5 levels, air filtration can help slow the progression of atherothrombosis, thereby potentially reducing the risk of heart attacks and other cardiovascular events.

Find a Location

Who is running the clinical trial?

University of Southern CaliforniaLead Sponsor
940 Previous Clinical Trials
1,603,866 Total Patients Enrolled
2 Trials studying Air Pollution
1,302 Patients Enrolled for Air Pollution
Duke UniversityOTHER
2,439 Previous Clinical Trials
3,065,748 Total Patients Enrolled
2 Trials studying Air Pollution
452 Patients Enrolled for Air Pollution
National Institute of Environmental Health Sciences (NIEHS)NIH
290 Previous Clinical Trials
1,232,845 Total Patients Enrolled
5 Trials studying Air Pollution
792 Patients Enrolled for Air Pollution

Media Library

HEPA filtration (Air Filtration) Clinical Trial Eligibility Overview. Trial Name: NCT05867381 — N/A
Air Pollution Research Study Groups: HEPA first and sham, Sham first and HEPA
Air Pollution Clinical Trial 2023: HEPA filtration Highlights & Side Effects. Trial Name: NCT05867381 — N/A
HEPA filtration (Air Filtration) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05867381 — N/A
~75 spots leftby Jun 2027